Inovio Pharmaceuticals, INC

Inovio Pharmaceuticals announced the pricing of a public offering of common stock and warrants, expecting to raise approximately $20.0 million.

Inovio Pharmaceuticals provides an estimated cash and cash equivalents of $36.7 million as of June 30, 2026, subject to final financial closing procedures.

Inovio Pharmaceuticals announced board-approved amendments to its bylaws, establishing a Lead Independent Director role and clarifying the Chairman's position, alongside reporting results from its 2026 Annual Meeting of Stockholders.

Inovio Pharmaceuticals announced first quarter 2026 financial results, highlighting the ongoing FDA review of its Biologics License Application for INO-3107 with a target PDUFA date of October 30, 2026, and updated cash runway into Q1 2027.

Inovio Pharmaceuticals has priced an underwritten public offering of common stock and warrants expected to raise approximately $17.5 million in gross proceeds.

Inovio Pharmaceuticals, Inc. has suspended and terminated the prospectus for its at-the-market offering, halting further stock sales.

Inovio Pharmaceuticals reported a net loss of $19.7 million for Q1 2026, while facing FDA review challenges for its lead drug candidate, INO-3107.

Inovio Pharmaceuticals reported significant net losses for Q3 2025, with cash reserves projected to last only into Q2 2026, raising substantial doubt about its ability to continue as a going concern.

Inovio Pharmaceuticals reported continued significant losses and expressed substantial doubt about its ability to continue as a going concern beyond Q2 2026, despite recent capital raises.

Inovio Pharmaceuticals reports a net loss of $19.7 million for Q1 2025 and anticipates current resources will fund operations into Q1 2026.

Inovio Pharmaceuticals' Q3 2024 report reveals a net loss of $25.2 million and a delay in BLA submission for INO-3107 due to a manufacturing issue.

Inovio Pharmaceuticals reported a net loss of $32.2 million for the second quarter of 2024 and provided updates on its clinical programs, including a delay in the BLA submission for INO-3107.

Inovio Pharmaceuticals reports a $84.9 million net loss for 2025 and faces substantial doubt about its ability to continue as a going concern, while its lead RRP candidate, INO-3107, encounters FDA questions on accelerated approval eligibility.

INOVIO Pharmaceuticals details its 2024 financial results and provides an update on its clinical programs, including plans for a BLA submission for INO-3107 in mid-2025.

Inovio Pharmaceuticals' 2023 annual report highlights a strategic shift towards key DNA medicine candidates, particularly INO-3107 for RRP, while managing significant financial losses.

Director Wendy L. Yarno of Inovio Pharmaceuticals, Inc. was granted stock options and restricted stock units on May 20, 2026, as part of the company's non-employee director compensation policy.

Jay Shepard, a Director at Inovio Pharmaceuticals, Inc., acquired 41,800 stock options and 34,200 restricted stock units.

Director Ann Miller of Inovio Pharmaceuticals, Inc. (INO) acquired stock options and restricted stock units under the company's incentive plan.

David B. Weiner, a Director at Inovio Pharmaceuticals, Inc., acquired 41,800 stock options and 34,200 restricted stock units.

Inovio Pharmaceuticals director Lota S. Zoth was granted stock options and restricted stock units under the company's incentive plan.

Director Simon X. Benito of Inovio Pharmaceuticals, Inc. acquired 41,800 stock options and 34,200 restricted stock units.

Inovio Pharmaceuticals announced its virtual Annual Meeting of Stockholders will be held on May 20, 2026, with key proposals including director elections and an equity incentive plan update.

Inovio Pharmaceuticals is holding its virtual Annual Meeting of Stockholders on May 20, 2025, seeking votes on director elections, ratification of the accounting firm, executive compensation, and an amendment to its incentive plan.

Inovio Pharmaceuticals announces its virtual Annual Meeting of Stockholders to be held on May 21, 2024, featuring proposals for director elections, ratification of auditor appointment, and an advisory vote on executive compensation.

Vanguard Capital Management has disclosed a beneficial ownership of 5.05% of Inovio Pharmaceuticals Inc. common stock as of June 30, 2026.

Highbridge Capital Management LLC has increased its beneficial ownership of Inovio Pharmaceuticals, Inc. common stock to 8.2%, primarily through the exercise of warrants.

Adage Capital Management, L.P. has reported a beneficial ownership of 5.84% in Inovio Pharmaceuticals, Inc., including shares issuable upon warrant exercise.

FMR LLC, through its subsidiaries, reports beneficial ownership of 13.5% of Inovio Pharmaceuticals Inc. common stock as of March 31, 2026.

The Vanguard Group has reduced its beneficial ownership in Inovio Pharmaceuticals Inc. to 4.96% as of December 31, 2025, triggering an amended Schedule 13G filing.

Janus Henderson Group plc has reported a 9.99% beneficial ownership stake in INOVIO Pharmaceuticals, Inc., primarily through shared voting and dispositive power.